Global Antidepressant Drugs Market: by Depression Disorder (Major Depressive Disorder, Obsessive-Compulsive Disorder, Panic Disorder), Product (Tricyclic Antidepressants, Selective Serotonin Reuptake Inhibitors, Serotonin-Norepinephrine Reuptake Inhibitors) —Forecast till 2027


Market Synopsis

Antidepressant are the class of drugs that reduces the symptoms of depressive disorders by modifying chemical imbalances of neurotransmitters in the brain. However, chemical imbalances may be responsible for changes in mood and behavior. Antidepressant are used to treat different conditions such as generalized anxiety disorder, depression, agitation, obsessive compulsive disorders (OCD), manic-depressive disorders, childhood enuresis (bedwetting), major depressive disorder, diabetic peripheral neuropathic pain, neuropathic pain, social anxiety disorder, posttraumatic stress disorder (PTSD) etc.


According to the Centers for Disease Control and Prevention (CDC), it was estimated that suicide cases are on rise in U.S specially with females with age group of 10-14 and 45-64. It is also predicted that more than 41 million Americans (1 in 8) taking at least one antidepressant.


Market Dynamics

There are various factors responsible for driving the growth of market such as growing stress levels, depression, and elevated alcoholism. According to the World Health Organization (WHO), it has been estimated that more than 300 million people suffer from depression and 260 million suffer from anxiety disorders and many of the people who live with both the conditions.

Growing percentage of crimes such sexual abuse, femicide and violence can further drive the growth of the market.

Moreover, Tremendous diagnosis of cancer and tumor patients that rises the incidence of depression among cancer patients will fuel the global antidepressant drugs market. Additionally, increasing geriatric population, and emergence of novel techniques for development of drugs with less side effects are some of the factors propelling the growth of the market. According to the united Nations, in 2017 it was estimated that 962 million people aged 60 or over in the world, comprising 13 % of the global population. The population aged 60 or above is increasing at the rate of about 3 per cent per year.

Furthermore, growing awareness related to the disease state and required clinical needs, and increasing number of people suffering from stress can boost the market growth.

However, poor effectiveness and safety profiles of drug, preference for non-pharmacological therapies, and growing number of patent expiration of antidepressant are some of the restraining factors hampering the growth of the market.

Market Segmentation

The global antidepressant drugs market is segmented into depression disorder and by product.

Based on the depression disorder, the market is segmented into major depressive disorder, obsessive-compulsive disorder, panic disorder, and others. Depressive disorder is expected to drive the market.

On the basis of product, the market is segmented into tricyclic antidepressants, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors. Tricyclic antidepressants is expected to hold the major share during the forecasted period.


Regional analysis

Geographically, the antidepressant drugs market is bifurcated into four major regions such as north America, Europe, Asia Pacific (APAC), and Latin America, Middle East & Africa (LAMEA).

North America is expected to hold the major share, as there is high presence of stress and depression factors in region such as U.S. Increasing level of the disorders in adults suffering from stress, suicidal feelings, serious psychological disorders, and anxiety drives the market in this region.

According to the Anxiety and Depression Association of America, it estimated that anxiety disorders are the most common mental illness in the U.S, affecting 40 million adults in the United States age 18 and older, or 18.1% of the population every year.

Asia Pacific is predicted to have the moderate growth due various factors such as marketing approval for new medicines that can positively impact the market especially in China, Australia, and Japan. Moreover, Japan is estimated to have the largest growing antidepressant drug market as a result of large aging population in this region.

The increasing technological advancement, reimbursement policies, and government support drives the market in Europe. Additionally, LAMEA is experiencing a slow growth due to poor infrastructural development and less government support.

Players Covered

The global antidepressant drugs market comprises some of the major players such as Alkermes Plc, Allergan Plc, Eli Lilly and Co., GlaxoSmithKline Plc, H. Lundbeck, Merck & Co., Inc., Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Takeda Pharmaceutical Co. Ltd.

The other prominent players in the market includes Opko Health, Intra-Cellular Therapies, Janssen Pharmaceuticals, Lupin, Abbott Laboratories, Novartis, Forest Laboratories, and AstraZeneca.


Antidepressant Drugs Market Segmentation

By Depression Disorder:

  • Major Depressive Disorder
  • Obsessive-Compulsive Disorder
  • Generalized Anxiety Disorder
  • Panic Disorder
  • Others


By Product:

  • Tricyclic Antidepressants
  • Selective Serotonin Reuptake Inhibitors
  • Serotonin-norepinephrine reuptake Inhibitors
  • Monoamine oxidase inhibitors
  • Serotonin antagonist and reuptake inhibitors
  • Others


By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • India
    • China
    • South Korea
    • Australia
    • Rest of Asia Pacific
  • Latin America Middle East and Africa (LAMEA)
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of the Middle East and Africa

Leave a Reply

Your email address will not be published. Required fields are marked *

error: Content is protected !!